目的 评价双氯芬酸钠栓和坦索罗辛联合治疗前列腺增生(BPH)患者并发急性尿潴留(AUR)的有效性.方法 选择急、门诊有AUR的BPH患者56例,留置导尿后随机分为A,B两组.A组28例使用双氯芬酸钠栓(25mg,bid,直肠给药)和坦索罗辛(0.2mg,qd).B组28例单服坦索罗辛(0.2mg,qd).3d后拔除导尿管,观察自主排尿情况.所有患者均在入院1h内抽血查血清C-反应蛋白浓度,并与无AUR的BPH患者进行比较.结果 A组有25例3d后能自主排尿,有效率为89％.B组28位患者中20例能自主排尿,有效率为71％.两组相比,差异有显著性(P＜0.01).AUR患者的C-反应蛋白浓度为(0.49±0.19)mg/dL,显著高于无AUR的患者(0.26±0.23)mg/dL.但在AUR患者中,C-反应蛋白浓度与前列腺大小、PSA值、潴留的尿量、年龄无相关性.两组无明显副作用事件发生.结论 非甾体抗炎药联合α1-受体阻滞剂治疗BPH伴AUR患者,较单用α1-受体阻滞剂更有效.%Objective To evaluate the effect and safety of the diclofenac sodium suppository associated with tamsulosin on patients suffering from acute urinary retention (AUR) caused by benign prostatic hyperplasia (BPH). Methods Patients with AUR due to BPH (total 56) were catheterized and randomized into two groups: Group A: The diclofenac sodium suppository and tamsulosin 0.2mg (28 patients); Group B: Tamsulosin 0.2mg (28 patients). Three days later, the catheter was removed, and patients' automatic micturition was evaluated. Furthermore, the serum C-reactive protein (CRP) level of all patients was measured and compared with that of the BPH patients without AUR. Results After removal of the catheter, 89 %(25/ 28) of the patients in Group A voided successfully, and the successful rate was more significant than that of the patients in Group B [71 %(20/28)]. Patients with AUR had significantly higher serum CRP level (0.49±0.19 mg/dL) than those without AUR (0.26 ±0.23 mg/dL). Conclusion The combination of the diclofenac sodium suppository and tamsulosin is safe and effective for AUR due to BPH .
展开▼
